Discover 381 paid clinical trials in Greenville, South Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 381
FeaturedActive & Responsive
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: Greenville SC, Charlotte NC, Monroe NC, Atlanta GA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819878
Phase 3, Recruiting
FeaturedActive & Responsive
Cardiovascular Disease Studies for Adults With High Blood Pressure, High Cholesterol, AFib, or Heart Failure
C. diff Vaccine Studies for Adults 65+ at Higher Risk of Infection
for
Clostridium Infections
Location: Spartanburg SC, Savannah GA, Omaha NE, Sioux City IA,
Sex: All
Age: 65+
Recruiting
Participants receive up to $1,470 for time and travel
FeaturedActive & Responsive
Weight Loss Studies for Adults With a BMI of 27+, Including People Managing Type 2 Diabetes or Sleep Apnea
for
Obesity, Overweight, Diabetes Mellitus, Type 2,
Location: Gaffney SC, Monroe NC, Durham NC, New Bern NC,
Sex: All
Age: 18+
Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Greenville SC, Charlotte NC, Marietta GA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06790693
Phase 3, Recruiting
Featured
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
for
Ulcerative Colitis
Location: Greenville SC, Atlanta GA, Pittsburgh PA, Cleveland OH,
Sponsor: AbbVie
Sex: All
Age: 2 - 17
Code: NCT07071519
Phase 3, Recruiting
Featured
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
for
Migraine
Location: Greenville SC, Charlotte NC, Atlanta GA, Savannah GA,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05125302
Phase 3, Recruiting
Featured
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)